PLGLB2

Across TCGA pan-cancer cohorts, PLGLB2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PLGLB2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PLGLB2 RNA is repressed in tumor relative to normal tissue. In most cancer types PLGLB2 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, KIRC, and CHOL are the cancer types where PLGLB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLGLB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	−1.683	<.001	8	view →
KIRC	All	All	+0.038	<.001	8	view →
CHOL	Male	All	−2.311	<.001	5	view →
STAD	All	II,III,IV	+0.069	.009	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PLGLB2–LIHC

Open the LIHC breakdown →